quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Snowflake Cortex Code Expands Towards Supporting Any Data, Anywhere

View original at finance.yahoo.com
Snowflake Cortex Code Expands Towards Supporting Any Data, Anywhere New updates to Cortex Code CLI support popular data systems dbt and Apache Airflow®…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than 12,600 customers around the globe, including hundreds of the world's largest companies, use Snowflake's AI Data Cloud

    80% confidence

  • Developers don't operate in a single system, and AI coding assistants shouldn't either. Modern data work spans multiple systems, teams, and workflows — and the tools we build have to reflect that reality.

    80% confidence

  • Cortex Code has transformed solution development at evolv Consulting by providing a direct, context-aware connection to the Snowflake ecosystem. This translated into over 500 hours in time saving – roughly $100,000 in value – in just the first 20 days of adoption.

    80% confidence

  • Snowflake has seen strong adoption of Cortex Code with over 4,400 new users since launch in November 2025

    80% confidence

  • Cortex Code is transforming how Braze approaches agentic analytics, with native understanding of datasets, schemas, and columns allowing engineers to spend less time on context and more time getting precise, actionable outputs

    80% confidence

Data points we hold from this source

Snowflake Inc. · customer count12600 customers

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Snowflake Cortex Code Expands Towards Supporting Any Data, Anywhere — Source | Via News | pt.VIA.NEWS